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Beware of using invalid 
transmission models to 
guide HIV health policy
Authors’ reply
We agree with Justin Okano and 
Sally Blower that every eﬀ ort must 
be made to ensure that important 
policy decisions are informed by valid 
models.
Okano and Blower note that the 
models in our analysis of expanded 
antiretroviral therapy make diﬀ erent 
future projections for HIV incidence 
between 2014 and 2033 (as shown 
in their ﬁ gure and in ﬁ gure S3 in the 
online appendix of our report). They 
contend that this ﬁ nding implies that 
at least some of the models must be 
invalid.
Although Okano and Blower note 
correctly that not all of these future 
projections will turn out to be close 
to what actually occurs, they are 
unable to identify now which ones 
will be wrong. Indeed, none of these 
incidence projections can be validated 
or invalidated on the basis of existing 
evidence, and it is of course impossible 
to know which trajectory, if any, will 
later prove to be correct.
We agree that we should only be 
interested in model predictions about 
the future if they faithfully reproduce 
past trends and present circumstances, 
to the extent that the available evidence 
allows us to discern these. In this case, 
the variation in incidence trends is 
the result of several transmission 
models, each of which synthesise the 
available epidemiological, behavioural, 
and biological evidence in a logically 
consistent manner. The ﬁ nding that 
the implementation of these models 
produces diﬀ erent results therefore 
represents genuine uncertainty about 
the future. We should seek to reduce 
this uncertainty and we reiterate our 
recommendation that the conclusions 
of our analyses be re-evaluated in light 
of new data as they become available.1
The need to understand the 
consequences of the existing un-
certainty makes it useful to apply 
several diﬀ erent models to the 
sample policy question. This approach 
was motivated by earlier work 
that documented the sometimes 
substantial diﬀ erences in the eﬀ ect 
of antiretroviral therapy in diﬀ erent 
models.2 To consider the eﬀ ect of 
uncertainty about model parameters 
is standard for policy analyses,3,4 but 
to account for uncertainty introduced 
by model structure is less common 
and might be especially important for 
dynamic disease transmission models.
In this context, the ﬁ nding that, 
despite this variation, a consistent 
policy recommendation emerges 
should rightly increase the level 
of conﬁ dence in that conclusion 
compared with the ﬁ ndings of one 
model. The alternatives of reliance on 
one model—or artiﬁ cially requiring 
models to produce similar future 
projections without the evi dentiary 
basis for doing so—are vulnerable to 
generating a false sense of security in 
ﬁ ndings, and it is of this that readers 
should beware.
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